Natera, Inc.

Equities

NTRA

US6323071042

Real-time Estimate Cboe BZX Other stock markets 05:56:54 12/02/26 am AEDT			5-day change	1st Jan Change
209.02 ^USD	-1.24%		+1.48%	-8.92%

07/02	Natera, Inc. Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes	CI
02/02	Natera Submits Premarket Approval Application for Molecular Residual Disease Test Signatera CDx	MT

Transcript : Natera, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02

Published on 06/10/2025 at 08:20 pm AEST - Modified on 06/10/2025 at 08:35 pm AEST

S&P Capital IQ

Presenter Speech
Matt Sykes (Analysts)

Welcome, everybody. Good afternoon. I'm Matt Sykes, the Life Science Tools and Diagnostics Analyst at Goldman Sachs, and I have the pleasure of welcoming Mike

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Natera, Inc.

07/02	Natera, Inc. Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes	CI
02/02	Natera Submits Premarket Approval Application for Molecular Residual Disease Test Signatera CDx	MT
02/02	Natera submits Signatera(TM) CDx PMA to FDA	RE
02/02	Natera, Inc. Submits Signatera CDx PMA to FDA	CI
29/01	Natera Completes Enrollment in Trial of Potential Non-Invasive Heart Rejection Test	MT
29/01	Natera Announces Completion of Enrollment in Randomized ACES-EMBTrial in Heart Transplantation	CI
21/01	Natera, Inc. Publishes Clinical Validation of Latitude?? Tissue-Free MRD Test in Colorectal Cancer	CI
14/01	Natera, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 04:30 PM
14/01	Natera Unveils AI Model to Enhance Cancer Recurrence Risk Assessment	MT
14/01	Natera, Inc. Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling	CI
13/01	Natera, Inc. to Scale AI Foundation Models in Precision Medicine with NVIDIA	CI
13/01	Natera to scale AI Foundation Models in precision medicine with Nvidia	RE
13/01	Sector Update: Health Care Stocks Lower Pre-Bell Monday	MT
13/01	Independence, Under Review
12/01	Natera Q4 Preliminary Revenue Rises; Shares Up Pre-Bell	MT
12/01	Natera, Inc. Provides Unaudited Sales Guidance for the Fourth Quarter and Full Year Ended December 31, 2025	CI
08/01	Exelixis, Natera to Collaborate on Phase 3 Colorectal Cancer Trial	MT
08/01	Exelixis and Natera to collaborate on Stellar-316, a phase 3 pivotal trial of zanzalintinib	RE
08/01	Exelixis, Inc. and Natera Announce to Collaborate on STELLAR-316, Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer	CI
07/01	Citigroup Initiates Natera at Buy With $300 Price Target	MT
06/01	Natera, Inc. Presents Updated Analyses from Altair Clinical Trial at 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium	CI
06/01	Natera Launches 21-Gene Fetal Focus Single-Gene NIPT, Powered by Ultra-S sensitive LinkedSNP?? Technology	CI
19/12	Natera, Inc. Announces Publication of Signatera Analysis from Randomized, Phase III CALGB/SWOG 80702 Study in Colorectal Cancer	CI
17/12	Natera, Inc. and Quantum Leap Healthcare Collaborative Announces the Publication of New Findings from the I-SPY 2 Trial in Nature Communications	CI
16/12	NeoGenomics Says Natera Withdraws Appeal in Patent Case	MT